Diagonal Bio AB Third Quarter Report (Q3 2024)
“One of the most exciting developments is our effort into a new application of our technology LAMPlify®—this time in the domain of swine diseases.”Summary of Q3 report 2024 2024-07-01 — 2024-09-30 (July — September 2024) ● Net sales amounted to 0 KSEK (0 KSEK), capitalised development contributedwith 248 KSEK (781 KSEK), and other operating income amounted to 0 KSEK (8 KSEK). ● Operating profit amounted to -1 242 KSEK (-2 605 KSEK). ● Operating profit per net weighted average share amounted to 0 SEK (-0.08 SEK). ● Cash flow during the third
Read original